v3.26.1
Consolidated Statements of Operations - USD ($)
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Revenue:    
Total revenue $ 6,841,250 $ 6,532,000
Operating expenses:    
Cost of services 4,282,167 3,645,565
Cost of goods sold 30,571 12,201
Selling, general and administrative expenses 7,691,151 8,065,801
Research and development expenses 4,880
Impairment of intangible assets 1,397,353
Loss on disposal of fixed assets 511,663
Depreciation and amortization 677,364 919,603
Total operating expenses 14,078,606 13,159,713
Loss from operations (7,237,356) (6,627,713)
Other income (expense):    
Gain from equity method joint ventures 31,294 9,045
Gain on changes in fair value 5,172,006
Gain on lease termination 94,551
Loss from debt extinguishment (2,135,854) (40,491)
Loss on issuance of warrants (943,862)
Gain on settlement of liability (Note 18) 929,500
Interest expense (1,302,074) (1,035,143)
Total other income (expenses) 1,751,010 (972,038)
Net loss before income taxes (5,486,346) (7,599,751)
Provision (benefit) for income taxes (150,371) 140,202
Net loss from continuing operations (5,335,975) (7,739,953)
Loss on disposal of NTI (Note 4) (1,534,517)
Loss on discontinued operations of NTI (Note 4) (16,452,562) (1,519,000)
Net loss (23,323,054) (9,258,953)
Preferred stock dividends and deemed dividends (1,807,170) (250,635)
Net loss attributable to common shareholders $ (25,130,224) $ (9,509,588)
Net loss from continuing operations per common share:    
Basic $ (45.57) $ (3,078.74)
Diluted (45.57) (3,078.74)
Net loss from discontinued operations per common share:    
Basic (153.63) (604.21)
Diluted (153.63) (604.21)
Net loss per common share:    
Basic (214.64) (3,782.65)
Diluted $ (214.64) $ (3,782.65)
Weighted average number of common shares outstanding:    
Basic 117,083 2,514
Diluted 117,083 2,514
Clinic Revenue [Member]    
Revenue:    
Total revenue $ 6,721,057 $ 6,450,431
Product [Member]    
Revenue:    
Total revenue $ 120,193 $ 81,569